CITIZEN: Medical organizations and doctors challenge the FDA’s approval of chemical abortion pill.

The spotlight of the legal proceedings has already exposed the FDA as putting politics first, rather than ensuring safety and protecting life.

When it comes to chemical abortion drugs, which now account for the majority of abortions within the nation, the Food and Drug Administration (FDA) has failed to fulfill its mission of “protecting the public health by ensuring the safety, efficacy, and security of… drugs, biological products, and medical devices.”

In 2000, the FDA wrongly approved the chemical abortion drug mifepristone. Since then, the FDA has moved on to dismantle the few safeguards that were in place at the time of approval. BUT representatives of 30,000 doctors are now pushing back and have challenged the FDA’s actions in a lawsuit.

On April 7, a federal district court judge in Texas halted the FDA’s approval of chemical abortion drugs. On April 12, the U.S. Court of Appeals for the 5th Circuit kept in place a portion of the order that protects the health and safety of women and girls by requiring the FDA to restore critical safeguards to chemical abortion drugs. On April 21, the U.S. Supreme Court allowed the FDA’s approval of chemical abortion drugs to remain in place while it is being challenged.

The Family Foundation, along with more than 30 pro-life organizations, had filed a “friend of the court” brief urging the U.S. Supreme Court to stop the FDA’s unlawful approval of chemical abortion drugs while the lawsuit from four medical organizations and four doctors proceeds.


  1. One in five women who take chemical abortion drugs experience complications, and they can be serious (4x that of surgical abortion).

  2. The FDA first approved chemical abortion drugs in 2000, with minimal restrictions and has since removed the few safeguards that were in place initially.

    Note: They did this by characterizing pregnancy as an “illness” and arguing that these drugs provide a “meaningful therapeutic benefit.”

  3. In 2021, under the pretext of COVID-19, the FDA “temporarily” removed the in-person requirement for distribution of these drugs… but has since made distribution through the mail, without even a single in-person doctor’s visit, permanent.

Click here to view and download the PDF of the print version of the Citizen paper.